Chargement en cours...

Bortezomib treatment induces a higher mortality rate in lupus model mice with a higher disease activity

BACKGROUND: Bortezomib (Bz) is a proteasome inhibitor that directly targets antibody-producing plasma cells. We recently reported the first randomized control trial that evaluated the effects of Bz in patients with systemic lupus erythematosus (SLE). In that study, we demonstrated that Bz treatment...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Arthritis Res Ther
Auteurs principaux: Ikeda, Tomoko, Fujii, Hiroshi, Nose, Masato, Kamogawa, Yukiko, Shirai, Tsuyoshi, Shirota, Yuko, Ishii, Tomonori, Harigae, Hideo
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2017
Sujets:
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5553803/
https://ncbi.nlm.nih.gov/pubmed/28800777
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-017-1397-7
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!